Skip to main content
TipRanks
Go Ultimate75% OFF

Tvardi Therapeutics (TVRD) Stock Price & Analysis

2,531 Followers

TVRD Stock Chart & Stats

$0.99$0.04(4.55%)
At close: 4:00 PM EST
$1$1.5Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$0.90 - $1.00
52-Week Range
$0.77 - $5.69
Previous Close
$0.95
Volume
N/A
Average Volume (3M)
286.18K
Market Cap
$12.64M
Enterprise Value
-$6.34M
Total Cash (Recent Filing)
$22.27M
Total Debt (Recent Filing)
$116.00K
Price to Earnings (P/E)
―
Beta
0.91
Next Earnings
Apr 06, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

FDA-supported Phase 2 Planning

FDA feedback reduces uncertainty around the nonclinical package and provides a clearer framework for TTI-109’s Phase 2 development. This is a meaningful regulatory milestone that can improve execution readiness, although clinical safety and efficacy remain unproven.

Low Current Leverage

Very low debt limits fixed financial obligations and reduces balance-sheet pressure while Tvardi advances its pipeline. Positive equity also provides a stronger current capital position than in prior periods, although the company remains dependent on external funding.

Reduced Cash Burn

The substantial reduction in annual operating cash burn indicates better spending discipline relative to the peak consumption years. Lower burn can extend the company’s ability to fund development activities, even though cash generation has not yet become positive.

Bears Say

No Current Commercial Revenue

The move to zero revenue shows that Tvardi currently lacks recurring commercial traction and remains reliant on pipeline progress rather than an established revenue base. Continued net losses further limit internal funding capacity and increase dependence on future financing.

Persistent Negative Cash Generation

Ongoing operating and free-cash-flow deficits require Tvardi to fund research and development through its existing resources or external capital. This weakens financial resilience and can constrain development flexibility if funding conditions become less supportive.

Volatile Capitalization History

The large swings in equity indicate a historically unstable capitalization profile and significant financing activity typical of a development-stage biotech. Although current leverage is low, this history signals that future pipeline investment may continue to depend on capital access.

Tvardi Therapeutics News

TVRD FAQ

What was Tvardi Therapeutics’s price range in the past 12 months?
Tvardi Therapeutics lowest stock price was $0.77 and its highest was $5.69 in the past 12 months.
What is Tvardi Therapeutics’s market cap?
Tvardi Therapeutics’s market cap is $12.64M.
When is Tvardi Therapeutics’s upcoming earnings report date?
Tvardi Therapeutics’s next earnings report is estimated for Apr 06, 2027 (not yet confirmed), which is in 135 days.
How were Tvardi Therapeutics’s earnings last quarter?
Tvardi Therapeutics released its earnings results on Nov 13, 2026. The company reported -$0.48 earnings per share for the quarter, beating the consensus estimate of -$0.571 by $0.091.
Is Tvardi Therapeutics overvalued?
According to Wall Street analysts Tvardi Therapeutics’s price is currently Undervalued.
Does Tvardi Therapeutics pay dividends?
Tvardi Therapeutics does not currently pay dividends.
What is Tvardi Therapeutics’s EPS estimate?
Tvardi Therapeutics’s EPS estimate is -0.46.
How many shares outstanding does Tvardi Therapeutics have?
Tvardi Therapeutics has 13,363,391 shares outstanding.
What happened to Tvardi Therapeutics’s price movement after its last earnings report?
Tvardi Therapeutics reported an EPS of -$0.48 in its last earnings report, beating expectations of -$0.571. Following the earnings report the stock price went up 2.165%.
Which hedge fund is a major shareholder of Tvardi Therapeutics?
Hedge funds hold Tvardi Therapeutics shares: the largest hedge-fund position in Tvardi Therapeutics is 72,401,875 shares, and hedge funds decreased their holdings by 181.0 shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology